Global Acute Coronary Syndrome Market - 2022-2029

Global Acute Coronary Syndrome Market - 2022-2029:

Market Overview

Acute Coronary Syndrome Market was valued at US$ 28,992.31 million in 2021 and is estimated to reach US$ 78,626.54 million by 2029, growing at a CAGR of 8.74% during the forecast period (2022-2029).

Acute coronary syndrome (ASC) occurs when a blood clot suddenly forms within a coronary artery, usually due to the acute rupture of an atherosclerotic plaque. The blood clot may produce partial or complete blockage of the artery, placing the heart muscle supplied by that artery in immediate jeopardy.

Market Dynamics

The global acute coronary syndrome market growth is driven by many factors, such as the rapid surge in acute coronary syndrome cases, the rising prevalence of chronic diseases and increasing cases of high blood pressure, hypertension and obesity.

The increasing prevalence of the chronic disease across the globe and rising technological advancements are driving the market growth.

The market is driven by the rising prevalence of chronic ailments like heart failure, cardiovascular disease, and coronary artery disease due to unhealthy lifestyles and changing environments worldwide. According to the National Health and Nutrition Examination Survey (NHANES) data (2020), an estimated 6.2 million American adults ≥20 years of age (2.2%) had heart failure. More than 5.7 million Americans suffer from heart failure, and approximately 915,000 new patients are diagnosed annually. For patients with advanced heart failure, ventricular assist devices support the weakened heart by pumping blood through the body.

According to the American Heart Association report 2022, Medicare patients (service fee) with coronary artery disease who received treatment at socioeconomically impoverished practices were at higher risk of being admitted for unstable angina. Hence these coronary artery diseases are increasing, leading to the growth of the acute coronary market.

Increasing technological advancements in acute coronary syndrome treatment are also fuelling the growth of cardiac assist devices globally. For instance, in Jun 2021, Abbott announced that the company could support the growing demand for mechanical circulatory support devices to treat advanced heart failure properly.

The high cost associated with acute coronary syndrome treatment will hamper the market’s growth.

However, in price-sensitive regions such as Asia, the high cost of acute coronary syndrome therapeutics may impact the market. In these areas, patients and doctors prefer less expensive therapies or surgeries. Acute coronary syndrome treatments are expensive. This is one of the major global challenges to the acute coronary syndrome market's growth.

COVID-19 Impact Analysis

The pandemic has also caused supply chain disruptions, impacting the world market for medical products. The pandemic has negatively impacted global financial expectations, supply chains, operations, and crisis response strategies. Due to lockdowns and travel restrictions brought on by the spread of COVID-19, makers of novel acute coronary syndromes treatment experienced problems. Because the spread of COVID-19 infections badly impacted major economies, acute coronary syndrome therapeutics production was greatly impacted.

Market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Even though COVID-19 harms the acute coronary syndrome industry, preparing and implementing backup plans as soon as possible for business operations is crucial.

Segment Analysis

The ST-elevation myocardial infarction segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

ST-elevation myocardial infarction shows significant growth, accounting for the largest market share, due to the regulatory approval for ST-elevation myocardial infarction drugs. For instance, in Jun 2020, AstraZeneca announced that Brilinta (ticagrelor) received approval from US Food and Drug Administration. Brilinta is used for reducing first stroke or heart attack risk in patients at high risk with coronary artery disease.

New technological advancements, novel pipelines, and clinical research in acute coronary syndrome treatments will also lead to market growth. For instance, in Aug 2022, AstraZeneca presented its novel results from the analysis of phase III trials of DAPA-HF and DELIVER that shows the mortality benefit of Farxiga over placebo in heart failure patients.

Geographical Analysis

The North American region holds the largest global acute coronary syndrome market.

North America dominates the acute coronary syndrome market and is expected to show a similar trend over the forecast period. The growth of North American acute coronary syndrome can be attributed to the rising prevalence of heart failure cases and the surge in the geriatric population. Strong healthcare infrastructure and an increase in research and development expenditure are to blame for this supremacy.

Furthermore, the rising prevalence of chronic diseases like myocardial infarction, unstable angina, etc., in this region due to unhealthy lifestyles and diets has propelled acute coronary syndrome treatment demand in the market. According to the American Heart Association report 2020, approximately 790,000 people in the U.S. have heart attacks yearly. The rising number of people suffering from cardiovascular diseases and growing technological advancements and mergers or acquisitions by key players boost the demand for acute coronary syndrome treatment in this region. For instance, in Jun 2021, Abiomed announced its acquisition of a precardiac catheter developer that provides less invasive options for treating patients with acute decompensated heart failure.

Competitive Landscape

The acute coronary syndrome market is highly competitive with local and global companies. Some key players contributing to the market’s growth are Teva Pharmaceuticals, Dr. Reddy’s Laboratories, Boehringer Ingelheim, Johnson & Johnson, Merck, Novartis, Amgen Inc., AbbVie Inc., AstraZeneca PLC and GlaxoSmithKline Plc among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the acute coronary syndrome market globally. For instance, in May 2022, Johnson and Johnson announced that its results from XARELTO (rivaroxaban), combined with the acetylsalicylic acid (XATOA) registry, were published in the European Heart Journal of the European Society of Cardiology. This study supports XARELTO’s dual pathway inhibition role in coronary artery disease patients.

In Sep 2022, Abiomed announced that U.S. FDA approved two clinical research Impella heart pumps that can be used in acute myocardial infarction.

Teva Pharmaceuticals.

Overview:

Teva Pharmaceuticals is a multinational pharmaceutical company established in 1901 and headquartered in Tel Aviv, Israel. It specializes in generic drugs (primary), active pharmaceutical ingredients and proprietary pharmaceuticals.

Product Portfolio:

Ranexa: Ranolazine is a medicine used to treat chest pain related to the heart, such as chronic stable angina. It improves the blood flow toward the heart and makes it work efficiently. It can be used in combination with other medicines.

The global acute coronary syndrome market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.